Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ102 in Advanced Ovarian Cancer and Solid Tumors
NCT07778498Phase 2Recruiting
- Sponsor
- Phrontline Biopharma
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 2
01
Overview
A Phase 2 trial of TJ102 (Phrontline Biopharma) in ovarian cancer, solid tumor, sponsored by Phrontline Biopharma. Started Sep 2026; status: recruiting.
02
Drugs
TJ102 (Phrontline Biopharma)
03
Conditions
ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT07778498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778498.